Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

135.30EUR
24 Apr 2015
Change (% chg)

€1.15 (+0.86%)
Prev Close
€134.15
Open
€134.65
Day's High
€135.85
Day's Low
€134.10
Volume
1,895,112
Avg. Vol
2,123,402
52-wk High
€146.45
52-wk Low
€94.22

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €111,886.00
Shares Outstanding(Mil.): 826.95
Dividend: 2.25
Yield (%): 1.66

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 32.66 41.06 41.71
EPS (TTM): 4.14 -- --
ROI: 7.50 16.86 16.20
ROE: 16.78 17.36 17.00
Search Stocks

BRIEF-Bayer files for regulatory approval in Japan of Xofigo

* Says files for regulatory approval in japan of Xofigo (radium 223 dichloride) prostate cancer treatment Further company coverage: (Reporting By Georgina Prodhan)

24 Apr 2015

Bayer MaterialScience fully on track to earn capital costs - CFO

DUESSELDORF, Germany, April 21 - Bayer's MaterialScience unit, which is preparing for a separate listing, is fully on track to earn its cost of capital this year, a key hurdle in gaining investors' trust, its finance chief said on Tuesday.

21 Apr 2015

BRIEF-Bayer to early redeem 1.3 bln eur bond issued in 2005

* Says first opportunity to repay the subordinated bond with a 5 pct coupon and a 100-year maturity issued in 2005 arises on July 29 Source text: http://bit.ly/1FJg8ro Further company coverage:

15 Apr 2015

BRIEF-Bayer to launch two late-stage trials of Copanlisib

* Says to commence two Copanlisib Phase III studies on patients with indolent non-hodgkin lymphoma Further company coverage:

14 Apr 2015

BRIEF-Bayer says China study confirms Eylea improves vision

* Says new phase 3 study in china confirms vision improvement for patients with wet age-related macular degeneration when receiving aflibercept solution (Eylea) for intravitreal injection

01 Apr 2015

BRIEF-Bayer issues 1.3 bln eur of 60-year hybrid bonds

* Bonds have a final maturity of 60 years and a coupon of 2.375 percent Source text: http://www.press.bayer.com/baynews/baynews.nsf/id/Bayer-issues-EUR-13-billion-in-hybrid-capital? Further company coverage:

30 Mar 2015

New Issue-Bayer Aktiengesellschaft prices 1.3 bln euro 2075 bond

where assigned, and hit the newskey (F9 on Reuters terminals)

30 Mar 2015

BRIEF-Bayer receives approval of Gadovist injection in Japan

* Receives approval for Gadovist (gadobutrol) injection in Japan Further company coverage:

26 Mar 2015

Bayer weighing options for consumer garden products

FRANKFURT - Germany's Bayer said it was considering strategic options for its home and garden consumer products business, maker of Baby Bio plant feed, as its crop protection arm focuses on professional customers.

20 Mar 2015

Bayer weighing options for consumer garden products

FRANKFURT - Germany's Bayer said it was considering strategic options for its home and garden consumer products business, maker of Baby Bio plant feed, as its crop protection arm focuses on professional customers.

20 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks